Quest Diagnostics (DGX) Share-based Compensation (2009 - 2026)

Quest Diagnostics has disclosed Share-based Compensation across 18 years of filings, most recently posting $20.0 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $20.0 million, down 9.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.0 million (down 2.27% YoY), and the FY2025 annual result was $88.0 million, changed 0.0% from the prior year.
• Share-based Compensation came in at $20.0 million for Q1 2026 at Quest Diagnostics, down from $25.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $27.0 million in Q4 2024 to a low of $16.0 million in Q2 2023.
• The 5-year median for Share-based Compensation is $20.0 million (2024), against an average of $20.6 million.
• Across the five-year window, Share-based Compensation declined 15.79% in 2023 and jumped 42.11% in 2024, its largest moves.
• Quest Diagnostics' Share-based Compensation stood at $22.0 million in 2022, then fell by 13.64% to $19.0 million in 2023, then surged by 42.11% to $27.0 million in 2024, then slipped by 7.41% to $25.0 million in 2025, then retreated by 20.0% to $20.0 million in 2026.
• The last three Share-based Compensation figures came in at $20.0 million (Q1 2026), $25.0 million (Q4 2025), and $20.0 million (Q3 2025), per Business Quant data.